Understanding how specific proteins affect DNA repair in aggressive breast cancer
Deciphering functions of the ATR-METTL3-BRCA1 Axis in genome instability and Tumorigenesis
This study is looking at how certain proteins help fix DNA damage in aggressive breast cancers, like triple negative breast cancer, to find new ways to improve treatment for patients based on their unique genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project ID | NIH-11098543 on NIH RePORTER |
What this research studies
This research investigates the role of the ATR-METTL3-BRCA1 axis in DNA damage repair, particularly in aggressive forms of breast cancer like triple negative breast cancer (TNBC). By examining how these proteins interact and contribute to genome stability, the study aims to uncover new therapeutic targets that could improve treatment outcomes. The approach involves analyzing the mechanisms by which BRCA1 and its partners respond to DNA damage, which is crucial for developing targeted therapies. Patients may benefit from insights gained about how to better treat their cancer based on their genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer or those with BRCA1 mutations.
Not a fit: Patients with non-aggressive forms of breast cancer or those without BRCA1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive breast cancer, particularly those with BRCA1 mutations.
How similar studies have performed: Previous research has shown promising results in targeting BRCA1 mutations in breast cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Torrance, United States
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, United States (Active)
Researchers
- Principal investigator: Wang, Hua — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Wang, Hua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.